Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.
about
Resource utilization and cost in a commercially insured population with schizophreniaComorbid mood, psychosis, and marijuana abuse disorders: a theoretical reviewLong-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonA retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization ratesIloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
P2860
Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Cost-effectiveness analysis of ...... Schizophrenia) study in Spain.
@en
Cost-effectiveness analysis of ...... conomic evaluation of the ZEUS
@nl
type
label
Cost-effectiveness analysis of ...... Schizophrenia) study in Spain.
@en
Cost-effectiveness analysis of ...... conomic evaluation of the ZEUS
@nl
prefLabel
Cost-effectiveness analysis of ...... Schizophrenia) study in Spain.
@en
Cost-effectiveness analysis of ...... conomic evaluation of the ZEUS
@nl
P2093
P2860
P1476
Cost-effectiveness analysis of ...... Schizophrenia) study in Spain.
@en
P2093
Carlos Rubio-Terrés
Javier Rejas
Jose Ramón Azanza
P2860
P304
P356
10.2165/00044011-200626080-00003
P577
2006-01-01T00:00:00Z